In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Sientra nets $108 mm in FOPO

Executive Summary

Sientra Inc. (medical aesthetics) netted $108mm through an upsized public offering of 8.5mm shares (including the overallotment) at $13.50. The company (which originally expected to gross $75mm through the offer) will use the proceeds to launch sales and marketing initiatives, expand commercialization in the US and globally, fund R&D efforts, and potentially for future product or company acquisitions. Earlier this month Sientra announced FDA approval for its Opus silicone gel breast implants (which will be manufactured in the US by partner Vesta), triggering a $10mm tranche of term debt under its separate July 2017 credit facility with MidCap Financial.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Implantable Devices
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies